Equity Overview
Price & Market Data
Price: $1.17
Daily Change: -$0.03 / 2.56%
Range: $1.13 - $1.22
Market Cap: $231,892,832
Volume: 2,150,076
Performance Metrics
1 Week: -4.10%
1 Month: 60.27%
3 Months: -22.00%
6 Months: -61.51%
1 Year: -59.66%
YTD: -46.82%
Company Details
Employees: 304
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.